Moody's Analytics Wins Two Categories at Data Management Awards 2018
Moody’s Analytics, a global provider of financial intelligence, has won Best Risk Data Aggregation Platform at the Data Management Awards 2018. Bureau van Dijk, a Moody’s Analytics company, won the award for Best Entity Data Solution.
We earned the prize for Best Risk Data Aggregation Platform for the breadth and strength of Moody’s Analytics risk data aggregation capabilities. Our CreditEdge™ platform provides early warning of credit deterioration of public entities and sovereigns globally, while members of the Moody’s Analytics Data Alliance can access one of the world’s largest collections of private credit risk data. Our RiskFoundation™ platform consolidates data from these and other sources to create a financial and risk datamart from which to view and measure enterprise risk across your portfolio.
“We’re honored to be recognized in the Data Management Awards,” said Dan Russell, Executive Director. “Our customers’ portfolios are increasingly diverse. They need to manage their risk more efficiently, on more entities, across more asset classes. Our award-winning risk data aggregation tools allow them to do that.”
The CreditEdge platform combines the industry-leading Moody’s Analytics EDF™ (Expected Default Frequency) model, a forward-looking probability of default measure, with cutting-edge analytics and more than 250 entity and industry data points. Customers can use the CreditEdge tool to measure the credit risk of public firms and sovereigns with advance early warning. More than 300 institutions (financial firms, asset managers, and regulatory and governmental agencies) across the globe use metrics from the CreditEdge platform.
The Moody’s Analytics Data Alliance is one of the world’s largest and most comprehensive data consortia. Member firms contribute and aggregate their data and collect credit risk benchmarking insight in return, drawn from a global database that includes more than 100 million financial statements representing more than 20 million private firms. The award-winning Data Alliance Portal allows member firms to securely upload data for all its asset classes, including Commercial & Industrial, Project Finance, Asset Finance, and Commercial Real Estate.
The Moody’s Analytics RiskFoundation data platform supplies the infrastructure for an exceptional risk management system. It brings together risk and finance data from different source systems into one common system of record – a “single source of truth” that lets customers examine their enterprise risk holistically. The RiskFoundation platform is a key component of numerous Moody’s Analytics solutions that support compliance with regulatory guidelines.
Bureau van Dijk took the prize for Best Entity Data Solution for the Orbis database. Orbis currently has information on 300 million entities in all countries, with an emphasis on private company information. Customers across the globe use Orbis to manage risk, achieve business growth, and improve efficiency, particularly around client and third-party onboarding and due diligence. As well as financial data, Orbis includes a vast range of complementary data which includes extensive corporate structures and ownership information.
The Data Management Awards, now in their sixth year, are presented by A-Team Group. They recognize firms that provide industry-leading data management solutions and services to capital markets participants. This win adds to the growing list of awards for Moody’s Analytics, including a top-five ranking and five solution category wins in the 2019 Chartis RiskTech100®.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit www.moodysanalytics.com.
Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.2 billion in 2017, employs approximately 12,600 people worldwide and maintains a presence in 42 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005146/en/
Contact information
Justin Bursztein
Moody’s Analytics Communications
+1.212.553.1163
Moody’s
Analytics Media Relations
moodysanalytics.com
twitter.com/moodysanalytics
linkedin.com/company/moodysanalytics
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom